Breast Cancer

Several studies have shown that Ki67 is an independent prognostic factor in patients with breast cancer, and Ki67 is included in the Oncotype DX test that estimates the likelihood of breast cancer recurrence and the need for chemotherapy.
Duloxetine relieved musculoskeletal symptoms in a significant proportion of postmenopausal patients with breast cancer receiving treatment with aromatase inhibitors (AIs) in a randomized trial (SWOG S1202).
Measuring the Ki67 protein, along with traditional risk factors such as tumor size and molecular characteristics, may make it possible to avoid sentinel node biopsy in women aged >50 years with breast cancer.

Women with clinicopathologic high-risk breast cancer had nearly a 50% reduction in prescription chemotherapy, with no increased risk for metastatic recurrence when a cancer gene–based assay was used to guide treatment decision­-making, according to new data presented at the 2016 American Association for Cancer Research meeting.

Women with clinicopathologic high-risk breast cancer had nearly a 50% reduction in prescription chemotherapy, with no increased risk for metastatic recurrence when a cancer gene–based assay was used to guide treatment decision­-making, according to new data presented at the 2016 American Association for Cancer Research meeting.

In patients with hormone receptor (HR)-positive, locally advanced or metastatic breast cancer, treatment with fulvestrant (Faslodex) demonstrated superiority over anastrozole (Arimidex) in achieving extended progression-free survival, according to a recent press release from AstraZeneca.

For protection against breast cancer recurrence, results from one recently reported study can best be described as “good news, bad news.”

A steroid mouthwash can reduce the incidence of stomatitis associated with the use of everoli­mus. Data from the first prospective trial of prophylactic use of a steroid mouth rinse demonstrated a 26% incidence of stomatitis among patients with metastatic breast cancer who used the mouth rinse versus 67% in historical controls.
San Antonio, TX–A scalp cooling system protects against chemotherapy-induced hair loss in patients with breast cancer, and contributes to their well-being. The effects of the DigniCap scalp cooling system in 110 patients were presented at the 2015 San Antonio Breast Cancer Symposium.
San Antonio, TX–A scalp cooling system protects against chemotherapy-induced hair loss in patients with breast cancer, and contributes to their well-being. The effects of the DigniCap scalp cooling system in 110 patients were presented at the 2015 San Antonio Breast Cancer Symposium.
Page 2 of 12
Results 11 - 20 of 116